GlycoMimetics starts phase one trial of GMI-1271 to treat multiple myeloma

US-based biotechnology company GlycoMimetics has commenced the phase one clinical trial of GMI-1271, combined with bortezomib-based chemotherapy to treat multiple myeloma.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news